A Phase 4 interventional study of Adipose derived stem cells suspention and Platelet rich plasma in Androgenetic Alopecia, sponsored by Assiut University. Status unknown at 1 site in Egypt. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2018-09-18.
Sponsored by Assiut University · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Alopecia with a site in Egypt — 9 open to participants now, 9 under way, 1 of them phase 3. Alopecia · Egypt.
Among the 25 studies in Alopecia with a site in Egypt, this one is the 10th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2018, is one of 5 in phase 4, and was the 3rd registered.
512 studies on the registry are indexed under Alopecia; 129 are open to participants now.
Browse Alopecia studies →9 of the 25 studies in Alopecia with a site in Egypt are open now. Recruiting first, the newest first:
Kasr El Aini Hospital · Sites in Egypt
Ages 18–50 · Men only · Healthy volunteers
Kasr El Aini Hospital · Sites in Egypt
Ages 18–50
Sohag University · Sites in Egypt
Ages 15–60 · Women only · Healthy volunteers
Sherief Ayman Hussein Shaamash · Sites in Egypt
Ages 18–40 · Men only
Cairo University · Sites in Egypt
Ages 12–50 · Healthy volunteers
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 75 Alopecia studies recruiting now, 25 (33%) set no upper age limit and 46 (61%) stop at 75 or younger; 9 take children under 18; 24 take healthy volunteers.
This study: 18 Years to 60 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 3 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 21 interventional studies, 63 across the 4 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 25 has an industry lead sponsor. The 10 most frequent:
Assiut University is the lead sponsor of 5,081 studies on the registry; 2,179 are open to participants now.
Of its 14 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Assiut University has 8 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 25 studies in Alopecia with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Androgenetic alopecia is the most common type of alopecia in both men and women. About 80 % of Caucasian men and 40-50 % of Caucasian women are affected by androgenetic alopecia. The psychological impact of hair loss due to Androgenetic alopecia can be profound.
Currently, two medications are Food and Drug Administration approved in the treatment of Androgenetic alopecia which are minoxidil, and finasteride. Both medications must be taken indefinitely for benefits to persist. Hair transplantation is the only current successful permanent option. Nowadays, the majority of surgeons use 2 techniques, the classic strip technique, and the follicular unit extraction technique. Advantages of follicular unit extraction over the strip technique are the lesser incidence of donor zone post-procedural discomfort and the barely visible scarring.
Platelet rich plasma is an autologous concentration of platelets in small volume of plasma and is an exciting therapeutic option for hair growth. Combining platelet rich plasma with follicular unit extraction surgery for the treatment of Androgenetic alopecia demonstrated that PRP is able to minimize the postsurgical follicle loss and potentiate the performance of grafted hairs.
Adipose derived stem cells are an effective mesenchymal stem cell population with enormous potential in different fields of regenerative medicine.
Adipose stem cells are needed to induce the proliferation of bulge stem cells of hair follicle. Furthermore, they can help in wound healing and vascular neogenesis.
Zanzottera et al. 2014 investigated the effect of adipose derived stem cells on wound healing and engraftment of the transplanted hair applied during hair restoration surgery for three patients with androgenetic alopecia. Despite their promising results, further clinical trials including larger number of patients are still needed to confirm their preliminary findings.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
suspension rich in adipose derived stem cells plus platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
Biological: Adipose derived stem cells suspention
platelet rich plasma will be injected at the recipient site during follicular unit extraction for treatment of androgenetic alopecia
Biological: Platelet rich plasma
application of adipose derived stem cells to the engrafted hair in hair transplantation surgery
application of autologous platelet rich plasma to the engrafted hair in hair transplantation surgery
hair growth
Evaluate the effect of adipose derived stem cells intradermally injected in the recipient site during follicular unit extraction for the treatment of androgenetic alopecia on transplanted hair growth in terms of hair density (number of hairs / cm2) in the transplanted region using folliscope.
Time frame: 12 months
hair shaft diameter
Evaluate the effect of adipose derived stem cells intradermally injected in the recipient site during follicular unit extraction for the treatment of androgenetic alopecia on transplanted hair shaft diameter in mm using folliscope.
Time frame: 12 months
Started Jan 2018 (actual). Primary completion is estimated for Jan 2021, 36 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.